Updated Story Medicare trustees credit higher-than-expected drug rebates and an enrollment shift from drug plans to Medicare Advantage for their lower projections for Part D expenditures compared to last year. However, the trustees still expect Part D spending to outpace other health care spending because expensive specialty drugs will drive up spending more than generic competition will lower it. “The Part D expenditure projections for the current report are mostly lower than last year’s projections primarily because...